Abstract: The present disclosure is directed to compounds of Formula (1): wherein m, n, Y, R1, R2, R3, R4 and R5 are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of Formula (I), as described herein, which are useful as voltage-gated potassium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

Abstract: A system for producing hydrocarbons may include a production control device positioned along a production flow line. The production control device may include an enclosure having an interior space and an isolation device disposed in the interior space. The isolation device may divide the interior space into an upper interior space and a lower interior space. The production control device may also include a first flow control device positioned in the upper interior space, and a second flow control device positioned in the upper interior space. The first flow control device may be responsive to a control signal transmitted via a control line from a surface location. The second flow control device may reactively block fluid flow from the lower interior section to the upper interior section when a pressure differential between the upper interior space and the lower interior space falls below a preset value.

Abstract: A system for producing hydrocarbons may include a production control device positioned along a production flow line. The production control device may include an enclosure having an interior space and an isolation device disposed in the interior space. The isolation device may divide the interior space into an upper interior space and a lower interior space. The production control device may also include a first flow control device positioned in the upper interior space, and a second flow control device positioned in the upper interior space. The first flow control device may be responsive to a control signal transmitted via a control line from a surface location. The second flow control device may reactively block fluid flow from the lower interior section to the upper interior section when a pressure differential between the upper interior space and the lower interior space falls below a preset value.

Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.